Android app Apple app link

Needham Lifts PT on Neumora Therapeutics (NMRA) to $8 From $6, Keeps a Buy Rating

By Yahoo! Finance   |   1 month ago
Needham Lifts PT on Neumora Therapeutics (NMRA) to $8 From $6, Keeps a Buy Rating

Neumora Therapeutics (NASDAQ:NMRA) is a promising stock under $5 with positive outlook. Analysts at Needham and Guggenheim raised price targets due to the company's strong pipeline and preclinical data showing potential in obesity treatment.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.